Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. The company’s lead product candidate is Tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent topical cream that is in Phase III clinical trials for the treatment of psoriasis and atopic dermatitis. Its product candidates in Phase I clinical trials include Cerdulatinib (DMVT-505), a dual inhibitor of the Janus kinase and spleen tyrosine kinase pathways for the treatment of vitiligo, as well as other inflammatory skin conditions, such as atopic dermatitis; and Oxybutynin/Pilocarpine (DMVT-504), an investigational oral therapy for the treatment of primary focal hyperhidrosis.